nched Marqibo through its existing haematology sales force. Tekmira is entitled to royalty payments based on the drug's commercial sales. Alnylam's LNP-Enabled Therapeutics; There are currently three LNP-based products in clinical development ALN-TTR02, ALN-VSP, and ALN-PCS02 targeting amyloidosis, liver cancer and high